Update on PET, CT imaging:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Elsevier Saunders
2007
|
| Schriftenreihe: | Radiologic clinics of North America
45,4 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | IX S., S. 609 - 749 zahlr. Ill., graph. Darst. |
| ISBN: | 9781416051206 1416051201 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV022869375 | ||
| 003 | DE-604 | ||
| 005 | 20071015 | ||
| 007 | t | ||
| 008 | 071008s2007 ad|| |||| 00||| eng d | ||
| 020 | |a 9781416051206 |9 978-1-4160-5120-6 | ||
| 020 | |a 1416051201 |9 1-4160-5120-1 | ||
| 035 | |a (OCoLC)173620775 | ||
| 035 | |a (DE-599)HBZHT015301018 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 050 | 0 | |a RM846 | |
| 245 | 1 | 0 | |a Update on PET, CT imaging |
| 264 | 1 | |a Philadelphia [u.a.] |b Elsevier Saunders |c 2007 | |
| 300 | |a IX S., S. 609 - 749 |b zahlr. Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Radiologic clinics of North America |v 45,4 | |
| 650 | 7 | |a Computertomografie |2 gtt | |
| 650 | 7 | |a Positronemissietomografie |2 gtt | |
| 650 | 4 | |a Cancer |x Tomography | |
| 650 | 4 | |a Diagnostic imaging | |
| 650 | 4 | |a Positron-Emission Tomography | |
| 650 | 4 | |a Tomography | |
| 650 | 4 | |a Tomography, Emission | |
| 830 | 0 | |a Radiologic clinics of North America |v 45,4 |w (DE-604)BV000003369 |9 45,4 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016074506&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016074506 | ||
Datensatz im Suchindex
| _version_ | 1804137127431110656 |
|---|---|
| adam_text | UPDATE ON PET/CT IMAGING
Contents
Staging of Lung Cancer 609
Jokke Wynants, Sigrid Stroobants, Christophe Dooms, and Johan Vansteenkiste
Imaging techniques play a vital role in the diagnosis, staging, and follow up of patients
who have lung cancer. For this purpose, PET has become an important adjunct to
conventional imaging techniques such as chest radiography, CT, ultrasonography, and
MR imaging. The ability of PET to differentiate the metabolic properties of tissues allows
more accurate assessment of undetermined lung lesions, mediastinal lymph nodes, or
extrathoracic abnormalities, tumor response after induction treatment, and detection of
disease recurrence.
Impact of PET on Radiation Therapy Planning in Lung Cancer 627
Michael P. Mac Manus and Rodney J. Hicks
The superiority of PET imaging to structural imaging in many cancers is rapidly
transforming the practice of radiotherapy planning, especially in lung cancer. Although
most lung cancers are potentially treatable with radiation therapy, only patients who
have truly locoregionally confined disease can be cured by this modality. PET improves
selection for high dose radiation therapy by excluding many patients who have
incurable distant metastasis or extensive locoregional spread. In those patients suitable
for definitive treatment, PET can help shape the treatment fields to avoid geographic
miss and minimize unnecessary irradiation of normal tissues. PET will allow for more
accurately targeted dose escalation studies in the future and could potentially lead to
better long term survival.
PET Versus PET/CT Dual Modality Imaging in Evaluation of Lung Cancer 639
Lutz S. Freudenberg, Sandra J. Rosenbaum, Thomas Beyer, Andreas Bockisch,
and Gerald Antoch
Non small cell lung cancer (NSCLC) accounts for approximately 80% of bronchogenic
malignancies. The choice of therapy options, including surgery, radiation therapy, and
chemotherapy—used alone or in combination—is based on the tumor stage.
Consequently, the accurate determination of tumor size, potential infiltration of
adjacent structures, mediastinal lymph node involvement, and the detection of distant
metastases are of central importance. The purpose of this article is to summarize the
accuracy of dual modality FDG PET/CT imaging in staging of NSCLC as compared with
FDG PET alone, and with FDG PET as well as CT read side by side. Furthermore, an
optimized PET/CT protocol for patients who have lung cancer is outlined.
F 18 Fluorodeoxyglucose Positron Emission Tomography Imaging for Primary
Breast Cancer and Loco Regional Staging 645
Norbert Avril and Lee P. Adler
Breast cancer is the most common female malignancy in Western countries. The
limitations of mammography, ultrasound and MR1 do not allow reliable identification
of primary breast cancer at early stages. Functional breast imaging with positron
emission tomography (PET) and F 18 fluorodeoxyglucose (FDG) enables the
visualization of increased glucose metabolism of breast cancer. However, despite the
successful identification of primary breast cancer, FDG PET provides a low sensitivity to
detect small tumors. Therefore, FDG PET does not allow screening of asymptomatic
women and cannot be used to exclude breast cancer in patients with suspicious breast
masses or abnormal mammography. FDG PET is a powerful tool for staging of breast
cancer patients, but does not detect micrometastases and small tumor infiltrated lymph
nodes. Nevertheless, in patients with locally advanced breast cancer, PET accurately
determines the extent of disease, particularly the loco regional lymph node status.
Advances in technology, for example the development of dedicated breast imaging
devices such as positron emission mammography, hold promise to improve the
detection of primary tumors in the future.
Diagnosis of Recurrent and Metastatic Disease using F 18
EluprQq^^c^eHft^trQn En^ , 659
William B. Eubank
One of the major strengths of F 18 fluorodeoxyglucose positron emission tomography
(FDG PET) in breast cancer imaging is in the evaluation of patients who have suspected
loco regional recurrence or distant metastasis. In general, FDG PET is more sensitive
than conventional imaging for the detection of recurrent disease. Because of its ability to
more accurately stage patients who have advanced breast cancer, FDG PET has
a significant impact on choice of treatment and management in this patient group.
Detection of Bone Metastases in Breast Cancer by Positron Emission Tomography 669
Holger Schirrmeister
Positron emission tomography (PET) is able to demonstrate changes in the metabolism
of malignant tumors and metastases before they become visible on anatomical imaging.
The skeleton is the most common site of distant metastases of breast cancer. There is
convincing evidence that FDG PET is more sensitive in detecting osteolytic metastases
than bone scintigraphy, whereas bone scintigraphy is more sensitive in detecting
osteoblastic metastases. Because both types of metastases can occur in breast cancer,
bone scintigraphy and FDG PET should be considered as complementary and can
currently be regarded as standard of care for staging in breast cancer patients, whereas
the decision to use F 18 fluoride PET should be made individually for each patient,
depending on the expected change of therapy management.
Normal and Abnormal Patterns pf 18F Fluorodeoxyglucose PET/CT in lymphpma 677
Rachel Bar Shalom
In spite of the high performance of 18F fluorodeoxyglucose (FDG) PET for the
evaluation of lymphoma, inherent limitations of this modality underscore the
additional value of PET/CT as an important tool in the assessment of this disease.
Accumulating data on the use of PET/CT in lymphoma indicate the contribution of
hybrid imaging to improved interpretation accuracy of PET using FDG and CT.
Knowledge of the normal and abnormal patterns of FDG PET/CT imaging and their
variability in patients with lymphoma is important to provide a comprehensive
clinically significant interpretation that has an impact on patient management and
potentially on outcome.
PETa^dPET/ainMansaenisrto^ ,_„., §89
Donald A. Podoloff and Homer A. Macapinlac
Within recent years, F 18 fluorodeoxyglucose (FDG) PET has become the most
important nuclear medicine and radiology imaging modality in the management of
lymphoma. FDG PET detects more disease sites and involved organs than conventional
staging procedures, including CT, and has a large influence on staging. FDG PET
performed during and after therapy seems to provide considerable prognostic
information. The impact on patient outcome is not clear, however, because no
controlled trials have yet been conducted and follow up periods are generally short.
Fluorine 18 Fluorodeoxyglucose PET/CT Patterns of Extranodal Involvement
in Patients vyjJb NMl rl9#fcLnJ«P^^ ..... 697
Einat Even Sapir, Genady Lievshitz, Chava Perry, Yair Herishanu, Hedva Lerman,
and Ur Metser
Lymphoma may originate in extranodal sites. Extranodal lymphoma may also be
secondary to and accompany nodal disease. Fluorine 18 fluorodeoxyglucose (18F FDG)
imaging has an essential role in the staging of lymphoma, in monitoring the response to
therapy, and in detection of recurrence. The introduction of 18F FDG PET/CT hybrid
imaging allows for accurate localization of disease and may be specifically beneficial for
the detection of unexpected extranodal sites of disease or exclusion of disease in the
presence of nonspecific extranodal CT findings. Accurate staging and localization often
dictate the appropriate treatment strategy in patients with lymphoma. Therefore, at any
stage in the course of the disease, the potential presence of extranodal disease should be
considered when interpreting 18F FDG PET/CT studies in patients with non Hodgkin
lymphoma and Hodgkin s disease.
Critical Role of 18F Labeled Fluorodeoxyglucose PET in the Management of Patients
with Arthroplasty 711
Hongming Zhuang, Hua Yang, and Abass Alavi
The most frequent complications after arthroplasty are aseptic loosening and infection.
It is often difficult to differentiate aseptic loosening from infection. The management of
these two distinct clinical identities is quite different, however. Treatment of aseptic
loosening usually requires one step revision surgery, whereas treatment of infection
requires antimicrobial therapy for an extended period before inserting a new prosthesis.
Infection associated with arthroplasty is a serious complication and should be treated
adequately before proceeding with a surgical intervention. PET with 18F labeled
fluorodeoxyglucose (FDG) has been proposed as an accurate technique for evaluating
painful arthroplasty. This review addresses the applications of FDG PET in such clinical
settings. In addition, the potential of PET in the assessing the viability of bone grafts in
revision arthroplasty is discussed.
Nonprosthesis Orthopedic Applications of 18F Fluoro 2 Deoxy D Glucose PET in the
J as mj j tmmNsfo „ 719
Johannes Meller, Carsten Oliver Sahlmann, Torsten Liersch, Peter Hao Tang, and Abass Alavi
This article describes the impact of [18F]2 fluoro 2 deoxy D glucose (FDG) PET in the
diagnosis of non prosthesis related orthopedic infections and inflammation. FDG PET
has an excellent sensitivity in the detection of osteomyelitis (OM). Early data indicate
that FDG PET may be more specific than MRI in diagnosing OM. The role of the
combination of FDG and PET CT in the diagnosis of OM is likely to be determined as
this combination is used on a routine basis. Early data from studies in rheumatoid
arthritis indicate that FDG PET is highly accurate in early diagnosis and that it provides
results comparable to the most advanced conventional techniques.
[18F]Fluorodeoxyglucose PET in Large Vessel Vasculitis 735
Martin A. Walter
[18F]fluorodeoxyglucose (FDG) PET is a noninvasive metabolic imaging modality based
on the regional distribution of [ 18FJFDG that is highly effective in assessing the activity
and extent of giant cell arteritis and Takayasu s arteritis, respectively. Metabolic imaging
using [18F] FDG PET has been shown to identify more affected vascular regions than
morphologic imaging with MRI in both diseases. The visual grading of vascular
[18FJFDG uptake helps to discriminate arteritis from atherosclerosis and therefore
provides high specificity. High sensitivity is attained by scanning during the active
inflammatory phase. Thus, [18FJFDG PET has the potential to develop into a valuable
tool in the diagnostic workup of giant cell arteritis and Takayasu s arteritis.
Index , , « 745
|
| adam_txt |
UPDATE ON PET/CT IMAGING
Contents
Staging of Lung Cancer 609
Jokke Wynants, Sigrid Stroobants, Christophe Dooms, and Johan Vansteenkiste
Imaging techniques play a vital role in the diagnosis, staging, and follow up of patients
who have lung cancer. For this purpose, PET has become an important adjunct to
conventional imaging techniques such as chest radiography, CT, ultrasonography, and
MR imaging. The ability of PET to differentiate the metabolic properties of tissues allows
more accurate assessment of undetermined lung lesions, mediastinal lymph nodes, or
extrathoracic abnormalities, tumor response after induction treatment, and detection of
disease recurrence.
Impact of PET on Radiation Therapy Planning in Lung Cancer 627
Michael P. Mac Manus and Rodney J. Hicks
The superiority of PET imaging to structural imaging in many cancers is rapidly
transforming the practice of radiotherapy planning, especially in lung cancer. Although
most lung cancers are potentially treatable with radiation therapy, only patients who
have truly locoregionally confined disease can be cured by this modality. PET improves
selection for high dose radiation therapy by excluding many patients who have
incurable distant metastasis or extensive locoregional spread. In those patients suitable
for definitive treatment, PET can help shape the treatment fields to avoid geographic
miss and minimize unnecessary irradiation of normal tissues. PET will allow for more
accurately targeted dose escalation studies in the future and could potentially lead to
better long term survival.
PET Versus PET/CT Dual Modality Imaging in Evaluation of Lung Cancer 639
Lutz S. Freudenberg, Sandra J. Rosenbaum, Thomas Beyer, Andreas Bockisch,
and Gerald Antoch
Non small cell lung cancer (NSCLC) accounts for approximately 80% of bronchogenic
malignancies. The choice of therapy options, including surgery, radiation therapy, and
chemotherapy—used alone or in combination—is based on the tumor stage.
Consequently, the accurate determination of tumor size, potential infiltration of
adjacent structures, mediastinal lymph node involvement, and the detection of distant
metastases are of central importance. The purpose of this article is to summarize the
accuracy of dual modality FDG PET/CT imaging in staging of NSCLC as compared with
FDG PET alone, and with FDG PET as well as CT read side by side. Furthermore, an
optimized PET/CT protocol for patients who have lung cancer is outlined.
F 18 Fluorodeoxyglucose Positron Emission Tomography Imaging for Primary
Breast Cancer and Loco Regional Staging 645
Norbert Avril and Lee P. Adler
Breast cancer is the most common female malignancy in Western countries. The
limitations of mammography, ultrasound and MR1 do not allow reliable identification
of primary breast cancer at early stages. Functional breast imaging with positron
emission tomography (PET) and F 18 fluorodeoxyglucose (FDG) enables the
visualization of increased glucose metabolism of breast cancer. However, despite the
successful identification of primary breast cancer, FDG PET provides a low sensitivity to
detect small tumors. Therefore, FDG PET does not allow screening of asymptomatic
women and cannot be used to exclude breast cancer in patients with suspicious breast
masses or abnormal mammography. FDG PET is a powerful tool for staging of breast
cancer patients, but does not detect micrometastases and small tumor infiltrated lymph
nodes. Nevertheless, in patients with locally advanced breast cancer, PET accurately
determines the extent of disease, particularly the loco regional lymph node status.
Advances in technology, for example the development of dedicated breast imaging
devices such as positron emission mammography, hold promise to improve the
detection of primary tumors in the future.
Diagnosis of Recurrent and Metastatic Disease using F 18
EluprQq^^c^eHft^trQn En^ , 659
William B. Eubank
One of the major strengths of F 18 fluorodeoxyglucose positron emission tomography
(FDG PET) in breast cancer imaging is in the evaluation of patients who have suspected
loco regional recurrence or distant metastasis. In general, FDG PET is more sensitive
than conventional imaging for the detection of recurrent disease. Because of its ability to
more accurately stage patients who have advanced breast cancer, FDG PET has
a significant impact on choice of treatment and management in this patient group.
Detection of Bone Metastases in Breast Cancer by Positron Emission Tomography 669
Holger Schirrmeister
Positron emission tomography (PET) is able to demonstrate changes in the metabolism
of malignant tumors and metastases before they become visible on anatomical imaging.
The skeleton is the most common site of distant metastases of breast cancer. There is
convincing evidence that FDG PET is more sensitive in detecting osteolytic metastases
than bone scintigraphy, whereas bone scintigraphy is more sensitive in detecting
osteoblastic metastases. Because both types of metastases can occur in breast cancer,
bone scintigraphy and FDG PET should be considered as complementary and can
currently be regarded as standard of care for staging in breast cancer patients, whereas
the decision to use F 18 fluoride PET should be made individually for each patient,
depending on the expected change of therapy management.
Normal and Abnormal Patterns pf 18F Fluorodeoxyglucose PET/CT in lymphpma 677
Rachel Bar Shalom
In spite of the high performance of 18F fluorodeoxyglucose (FDG) PET for the
evaluation of lymphoma, inherent limitations of this modality underscore the
additional value of PET/CT as an important tool in the assessment of this disease.
Accumulating data on the use of PET/CT in lymphoma indicate the contribution of
hybrid imaging to improved interpretation accuracy of PET using FDG and CT.
Knowledge of the normal and abnormal patterns of FDG PET/CT imaging and their
variability in patients with lymphoma is important to provide a comprehensive
clinically significant interpretation that has an impact on patient management and
potentially on outcome.
PETa^dPET/ainMansaenisrto^ ,_„., §89
Donald A. Podoloff and Homer A. Macapinlac
Within recent years, F 18 fluorodeoxyglucose (FDG) PET has become the most
important nuclear medicine and radiology imaging modality in the management of
lymphoma. FDG PET detects more disease sites and involved organs than conventional
staging procedures, including CT, and has a large influence on staging. FDG PET
performed during and after therapy seems to provide considerable prognostic
information. The impact on patient outcome is not clear, however, because no
controlled trials have yet been conducted and follow up periods are generally short.
Fluorine 18 Fluorodeoxyglucose PET/CT Patterns of Extranodal Involvement
in Patients vyjJb NMl rl9#fcLnJ«P^^ . 697
Einat Even Sapir, Genady Lievshitz, Chava Perry, Yair Herishanu, Hedva Lerman,
and Ur Metser
Lymphoma may originate in extranodal sites. Extranodal lymphoma may also be
secondary to and accompany nodal disease. Fluorine 18 fluorodeoxyglucose (18F FDG)
imaging has an essential role in the staging of lymphoma, in monitoring the response to
therapy, and in detection of recurrence. The introduction of 18F FDG PET/CT hybrid
imaging allows for accurate localization of disease and may be specifically beneficial for
the detection of unexpected extranodal sites of disease or exclusion of disease in the
presence of nonspecific extranodal CT findings. Accurate staging and localization often
dictate the appropriate treatment strategy in patients with lymphoma. Therefore, at any
stage in the course of the disease, the potential presence of extranodal disease should be
considered when interpreting 18F FDG PET/CT studies in patients with non Hodgkin
lymphoma and Hodgkin's disease.
Critical Role of 18F Labeled Fluorodeoxyglucose PET in the Management of Patients
with Arthroplasty 711
Hongming Zhuang, Hua Yang, and Abass Alavi
The most frequent complications after arthroplasty are aseptic loosening and infection.
It is often difficult to differentiate aseptic loosening from infection. The management of
these two distinct clinical identities is quite different, however. Treatment of aseptic
loosening usually requires one step revision surgery, whereas treatment of infection
requires antimicrobial therapy for an extended period before inserting a new prosthesis.
Infection associated with arthroplasty is a serious complication and should be treated
adequately before proceeding with a surgical intervention. PET with 18F labeled
fluorodeoxyglucose (FDG) has been proposed as an accurate technique for evaluating
painful arthroplasty. This review addresses the applications of FDG PET in such clinical
settings. In addition, the potential of PET in the assessing the viability of bone grafts in
revision arthroplasty is discussed.
Nonprosthesis Orthopedic Applications of 18F Fluoro 2 Deoxy D Glucose PET in the
J as mj j tmmNsfo „ 719
Johannes Meller, Carsten Oliver Sahlmann, Torsten Liersch, Peter Hao Tang, and Abass Alavi
This article describes the impact of [18F]2 fluoro 2 deoxy D glucose (FDG) PET in the
diagnosis of non prosthesis related orthopedic infections and inflammation. FDG PET
has an excellent sensitivity in the detection of osteomyelitis (OM). Early data indicate
that FDG PET may be more specific than MRI in diagnosing OM. The role of the
combination of FDG and PET CT in the diagnosis of OM is likely to be determined as
this combination is used on a routine basis. Early data from studies in rheumatoid
arthritis indicate that FDG PET is highly accurate in early diagnosis and that it provides
results comparable to the most advanced conventional techniques.
[18F]Fluorodeoxyglucose PET in Large Vessel Vasculitis 735
Martin A. Walter
[18F]fluorodeoxyglucose (FDG) PET is a noninvasive metabolic imaging modality based
on the regional distribution of [ 18FJFDG that is highly effective in assessing the activity
and extent of giant cell arteritis and Takayasu's arteritis, respectively. Metabolic imaging
using [18F] FDG PET has been shown to identify more affected vascular regions than
morphologic imaging with MRI in both diseases. The visual grading of vascular
[18FJFDG uptake helps to discriminate arteritis from atherosclerosis and therefore
provides high specificity. High sensitivity is attained by scanning during the active
inflammatory phase. Thus, [18FJFDG PET has the potential to develop into a valuable
tool in the diagnostic workup of giant cell arteritis and Takayasu's arteritis.
Index , , « 745 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV022869375 |
| callnumber-first | R - Medicine |
| callnumber-label | RM846 |
| callnumber-raw | RM846 |
| callnumber-search | RM846 |
| callnumber-sort | RM 3846 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| ctrlnum | (OCoLC)173620775 (DE-599)HBZHT015301018 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01392nam a2200385 cb4500</leader><controlfield tag="001">BV022869375</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20071015 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">071008s2007 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416051206</subfield><subfield code="9">978-1-4160-5120-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416051201</subfield><subfield code="9">1-4160-5120-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)173620775</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HBZHT015301018</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM846</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Update on PET, CT imaging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Elsevier Saunders</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">IX S., S. 609 - 749</subfield><subfield code="b">zahlr. Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Radiologic clinics of North America</subfield><subfield code="v">45,4</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Computertomografie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Positronemissietomografie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Tomography</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diagnostic imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Positron-Emission Tomography</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tomography</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tomography, Emission</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Radiologic clinics of North America</subfield><subfield code="v">45,4</subfield><subfield code="w">(DE-604)BV000003369</subfield><subfield code="9">45,4</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016074506&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016074506</subfield></datafield></record></collection> |
| id | DE-604.BV022869375 |
| illustrated | Illustrated |
| index_date | 2024-07-02T18:46:36Z |
| indexdate | 2024-07-09T21:07:21Z |
| institution | BVB |
| isbn | 9781416051206 1416051201 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016074506 |
| oclc_num | 173620775 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | IX S., S. 609 - 749 zahlr. Ill., graph. Darst. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Elsevier Saunders |
| record_format | marc |
| series | Radiologic clinics of North America |
| series2 | Radiologic clinics of North America |
| spelling | Update on PET, CT imaging Philadelphia [u.a.] Elsevier Saunders 2007 IX S., S. 609 - 749 zahlr. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Radiologic clinics of North America 45,4 Computertomografie gtt Positronemissietomografie gtt Cancer Tomography Diagnostic imaging Positron-Emission Tomography Tomography Tomography, Emission Radiologic clinics of North America 45,4 (DE-604)BV000003369 45,4 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016074506&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Update on PET, CT imaging Radiologic clinics of North America Computertomografie gtt Positronemissietomografie gtt Cancer Tomography Diagnostic imaging Positron-Emission Tomography Tomography Tomography, Emission |
| title | Update on PET, CT imaging |
| title_auth | Update on PET, CT imaging |
| title_exact_search | Update on PET, CT imaging |
| title_exact_search_txtP | Update on PET, CT imaging |
| title_full | Update on PET, CT imaging |
| title_fullStr | Update on PET, CT imaging |
| title_full_unstemmed | Update on PET, CT imaging |
| title_short | Update on PET, CT imaging |
| title_sort | update on pet ct imaging |
| topic | Computertomografie gtt Positronemissietomografie gtt Cancer Tomography Diagnostic imaging Positron-Emission Tomography Tomography Tomography, Emission |
| topic_facet | Computertomografie Positronemissietomografie Cancer Tomography Diagnostic imaging Positron-Emission Tomography Tomography Tomography, Emission |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016074506&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000003369 |